Beryl Drugs Stock Screener | Share Price & Fundamental Analysis
BERLDRG
Pharmaceuticals
Screen Beryl Drugs share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹22.63
▲
0.58 (2.63%)
Market Cap
₹11.78 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
1.20
EPS (TTM)
₹1.14
Dividend Yield
-
Debt to Equity
0.50
52W High
₹36.63
52W Low
₹17.48
Operating Margin
4.00%
Profit Margin
-
Revenue (TTM)
₹21.00
EBITDA
₹2.00
Net Income
-
Total Assets
₹16.00
Total Equity
₹10.00
Beryl Drugs Share Price History - Stock Screener Chart
Screen BERLDRG historical share price movements with interactive charts. Analyze price trends and patterns.
Beryl Drugs Company Profile - Fundamental Screener
Screen Beryl Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BERLDRG shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE415H01017
Beryl Drugs Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen BERLDRG balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 16 | 18 | 18 | 18 | 19 | 17 | 15 | 11 | 10 | 10 |
| Current Assets | 9 | 10 | 10 | 11 | 10 | 8 | 5 | 7 | 7 | 6 |
| Fixed Assets | 6 | 6 | 6 | 6 | 8 | 9 | 2 | 2 | 2 | 2 |
| Liabilities | ||||||||||
| Total Liabilities | 16 | 18 | 18 | 18 | 19 | 17 | 15 | 11 | 10 | 10 |
| Current Liabilities | 2 | 3 | 3 | 2 | 3 | 3 | 2 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 10 | 9 | 8 | 7 | 8 | 8 | 8 | 7 | 6 | 7 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 4 | 4 | 3 | 2 | 3 | 3 | 2 | 2 | 1 | 2 |
Screen BERLDRG income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21 | 23 | 27 | 27 | 15 | 14 | 13 | 13 | 16 | 11 | 14 | 14 |
| Expenses | 18 | 20 | 25 | 25 | 14 | 13 | 12 | 12 | 14 | 11 | 13 | 13 |
| EBITDA | 2 | 3 | 3 | 2 | 1 | 2 | 1 | 1 | 2 | 0 | 1 | 1 |
| Operating Profit % | 4.00% | 6.00% | 9.00% | 7.00% | 3.00% | 10.00% | 7.00% | 8.00% | 7.00% | -1.00% | 4.00% | 6.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 1 | 1 | -1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 1 | 1 | 1 | -1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| EPS | 0.50 | 1.14 | 1.52 | 1.51 | -1.30 | 0.47 | 0.09 | 1.16 | 1.96 | -0.88 | 0.33 | 0.17 |
Beryl Drugs Cash Flow Screener - Liquidity Fundamentals
Screen BERLDRG cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 3 | 1 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Investing Activities | 0 | -1 | -1 | 1 | 0 | -2 | -5 | 0 | 0 | 0 |
| Financing Activities | -2 | 0 | -1 | 0 | -1 | 2 | 2 | 0 | 0 | 0 |
| Net Cash Flow | 1 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 0 |
Screen BERLDRG shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 68.53% | 68.69% | 68.71% | 66.26% | 68.06% | 67.92% | 68.35% | 67.89% |
| Other Holding | 5.08% | 4.93% | 4.91% | 7.35% | 5.55% | 5.70% | 5.26% | 5.73% |
| Shareholder Count | 7,431 | 7,415 | 7,446 | 7,257 | 7,325 | 7,364 | 7,429 | 6,894 |
Beryl Drugs Dividend Screener - Share Yield Analysis
Screen BERLDRG dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Beryl Drugs Index Membership - Market Screener Classification
Screen BERLDRG by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Beryl Drugs Market Events Screener - Corporate Actions
Screen BERLDRG market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -16.04% | ||
| Annual General Meeting | NA | -1.84% | ||
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 1.70% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -3.22% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -4.64% |
| 2025-02-08 | 2025-02-08 | Quarterly Result Announcement | NA | -6.59% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | 0.30% |
Beryl Drugs Competitors Screener - Peer Comparison
Screen BERLDRG competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 424,634 | 39.93 | 54,729 | 9.71% | 10,980 | 49.55 |
| Divis Laboratories | 172,860 | 69.20 | 9,712 | 18.67% | 2,191 | 56.33 |
| Torrent Pharmaceuticals | 129,151 | 60.10 | 11,539 | 6.99% | 1,911 | 61.47 |
| Cipla | 122,205 | 22.55 | 28,410 | 7.12% | 5,291 | 49.47 |
| Dr Reddys Laboratories | 107,114 | 18.60 | 33,741 | 16.73% | 5,725 | 60.05 |
| Lupin | 97,120 | 22.34 | 22,910 | 13.74% | 3,306 | 65.28 |
| Zydus Life Science | 92,392 | 18.40 | 23,511 | 18.55% | 4,615 | 40.07 |
| Mankind Pharma | 90,241 | 50.59 | 12,744 | 20.90% | 2,007 | 45.53 |
| Aurobindo Pharma | 71,119 | 20.79 | 32,346 | 9.43% | 3,484 | 59.88 |
| Alkem Laboratories | 67,243 | 27.59 | 13,458 | 3.70% | 2,216 | 49.80 |
Beryl Drugs Company Announcements - News Screener
Screen BERLDRG latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-13 | UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2025 | View |
| 2025-11-13 | Board Meeting Outcome for OUTCOME OF BOARD MEETING | View |
| 2025-11-05 | Board Meeting Intimation for Consider And Approve The Unaudited Financial Results For The Quarter Ended 30Th September 2025 | View |
| 2025-10-07 | Compliance-57 (5) : intimation after the end of quarter | View |
| 2025-10-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-02 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-30 | Closure of Trading Window | View |
| 2025-09-30 | APPOINTMENT OF MRS. DIPIKA KATARIA AS SECRETARIAL AUDITOR OF THE COMPANY FOR A PERIOD OF FIVE YEARS | View |
| 2025-09-30 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-09-30 | PROCEEDINGS OF 32ND ANNUAL GENERAL MEETING OF THE COMPANY | View |
| 2025-09-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-09-03 | Reg. 34 (1) Annual Report. | View |
| 2025-09-02 | NOTICE OF EVOTING FACILITY FOR 32ND ANNUAL GENERAL MEETING 2025 | View |
| 2025-09-02 | FIXES RECORD DATE FOR THE PURPOSE OF ANNUAL GENERAL MEETING OF THE COMPANY 23RD SEPTEMBER 2025 | View |
| 2025-09-02 | FIXES BOOK CLOSURE FOR THE PURPOSE OF ANNUAL GENERAL MEETING OF THE COMPANY FROM 24TH SEPTEMBER 2025 TO 30TH SEPTEMBER 2025 | View |
| 2025-09-02 | 32ND ANNUAL GENERAL MEETING OF THE COMPANY WILL BE HELD ON 30TH SEPTEMBER 2025 AT 11:00 AM AT Kanchan Palace Community Hall Nipania Ring Road Indore (M.P) | View |
| 2025-09-02 | Board Meeting Outcome for OUTCOME OF BOARD MEETING | View |
| 2025-08-25 | Board Meeting Intimation for Consideration And Approval Of The Board Report And Other Matters Related To 32Nd Annual General Meeting Of The Company. | View |